Search

Your search keyword '"Choe, Jason"' showing total 16 results
Start Over Author "Choe, Jason"
16 results on '"Choe, Jason"'

2. Utility of a fusion protein T‐cell co‐stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center

Author

Oren, Daniel, primary, Uriel, Matan, additional, Moeller, Cathrine M., additional, Valledor, Andrea Fernandez, additional, DeFilippis, Ersilia M., additional, Lotan, Dor, additional, Colombo, Paolo C., additional, Yuzefpolskaya, Melana, additional, Topkara, Veli K., additional, Clerkin, Kevin J., additional, Raikhelkar, Jayant K., additional, Fried, Justin A., additional, Oh, David (Kyung Taek), additional, Bae, David, additional, Lin, Eddie, additional, Theodoropoulos, Kleanthis, additional, Naka, Yoshifumi, additional, Takeda, Koji, additional, Choe, Jason, additional, Jennings, Douglas L., additional, Majure, David, additional, Latif, Farhana, additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2024
Full Text
View/download PDF

3. Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation.

Author

Huang, Xinyi, Salerno, David, Kovac, Danielle, Scheffert, Jenna, Hedvat, Jessica, Carver, Bayleigh, Choe, Jason, Shertel, Tara, Yuzefpolskaya, Melana, Colombo, Paolo C., and Jennings, Douglas L.

Subjects
HEART transplant recipients, HEART transplantation, LIVER transplantation, KIDNEY transplantation, TRANSPLANTATION of organs, tissues, etc., FOCAL segmental glomerulosclerosis
Abstract

Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival. Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months. Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients. Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation.

Author

Donald, Elena M., Driggin, Elissa, Choe, Jason, Batra, Jaya, Vargas, Fabian, Lindekens, Jordan, Fried, Justin A., Raikhelkar, Jayant K., Bae, David J., Oh, Kyung T., Yuzefpolskaya, Melana, Colombo, Paolo C., Latif, Farhana, Sayer, Gabriel, Uriel, Nir, Clerkin, Kevin J., and DeFilippis, Ersilia M.

Subjects
HEART transplantation, TYPE 2 diabetes, GLUCAGON-like peptide-1 agonists, WEIGHT loss, GLYCEMIC control
Abstract

Background: The use of glucagon‐like‐peptide 1 receptor agonists (GLP1‐RA) has dramatically increased over the past 5 years for diabetes mellitus type 2 (T2DM) and obesity. These comorbidities are prevalent in adult heart transplant (HT) recipients. However, there are limited data evaluating the efficacy of this drug class in this population. The aim of the current study was to describe cardiometabolic changes in HT recipients prescribed GLP1‐RA at a large‐volume transplant center. Methods: We retrospectively reviewed all adult HT recipients who received GLP1‐RA after HT for a minimum of 1‐month. Cardiometabolic parameters including body mass index (BMI), lipid panel, hemoglobin A1C, estimated glomerular filtration rate (eGFR), and NT‐proBNP were compared prior to initiation of the drug and at most recent follow‐up. We also evaluated for significant dose adjustments to immunosuppression after drug initiation and adverse effects leading to drug discontinuation. Results: Seventy‐four patients were included (28% female, 53% White, 20% Hispanic) and followed for a median of 383 days [IQR 209, 613] on a GLP1‐RA. The majority of patients (n = 56, 76%) were prescribed semaglutide. The most common indication for prescription was T2DM alone (n = 33, 45%), followed by combined T2DM and obesity (n = 26, 35%). At most recent follow‐up, mean BMI decreased from 33.3 to 31.5 kg/m2 (p < 0.0001), HbA1C from 7.3% to 6.7% (p = 0.005), LDL from 78.6 to 70.3 mg/dL (p = 0.018) and basal insulin daily dose from 32.6 to 24.8 units (p = 0.0002). Conclusion: HT recipients prescribed GLP1‐RA therapy showed improved glycemic control, weight loss, and cholesterol levels during the study follow‐up period. GLP1‐RA were well tolerated and were rarely associated with changes in immunosuppression dosing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era

Author

Hedvat, Jessica, primary, Lange, Nicholas W., additional, Salerno, David M., additional, DeFilippis, Ersilia M., additional, Kovac, Danielle, additional, Corbo, Heather, additional, Chen, Justin K., additional, Choe, Jason Y., additional, Lee, Jennifer H., additional, Anamisis, Anastasia, additional, Jennings, Douglas L., additional, Codispodo, Giovanna, additional, Shertel, Tara, additional, Brown, Robert S., additional, and Pereira, Marcus R., additional

Published
2022
Full Text
View/download PDF

6. Letermovir for cytomegalovirus prophylaxis in high‐risk heart transplant recipients

Author

Golob, Stephanie, primary, Batra, Jaya, additional, DeFilippis, Ersilia M., additional, Uriel, Matan, additional, Carey, Matt, additional, Gaine, Maureen, additional, Mabasa, Angelo, additional, Fried, Justin, additional, Raikelkar, Jayant, additional, Restaino, Susan, additional, Hi Lee, Sun, additional, Latif, Farhana, additional, Yuzefpolskaya, Melana, additional, Colombo, Paolo C., additional, Choe, Jason, additional, Majure, David, additional, Jennings, Douglas, additional, Pereira, Marcus R., additional, Clerkin, Kevin, additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2022
Full Text
View/download PDF

8. Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants

Author

Lange, Nicholas W., primary, Salerno, David M., additional, Jennings, Douglas L., additional, Choe, Jason, additional, Hedvat, Jessica, additional, Kovac, Danielle (Bley), additional, Scheffert, Jenna, additional, Shertel, Tara, additional, Ratner, Lloyd E., additional, Brown, Robert S., additional, and Pereira, Marcus R., additional

Published
2022
Full Text
View/download PDF

9. PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

Author

Jennings, Douglas L., primary, Sultan, Lina, additional, Mingov, Jennifer, additional, Choe, Jason, additional, Latif, Farhana, additional, Restaino, Susan, additional, Clerkin, Kevin, additional, Habal, Marlena V., additional, Colombo, Paolo C., additional, Yuzefpulskaya, Melana, additional, Sayer, Gabriel, additional, Uriel, Nir, additional, and Baker, William L., additional

Published
2022
Full Text
View/download PDF

10. Nitazoxanide treatment for norovirus infection in solid organ transplant recipients

Author

Hedvat, Jessica, primary, Salerno, David M., additional, Kovac, Danielle, additional, Scheffert, Jenna L., additional, Corbo, Heather, additional, Chen, Justin K., additional, Choe, Jason Y., additional, Jennings, Douglas L., additional, Anamisis, Anastasia, additional, Liu, Esther C., additional, Lee, Jennifer H., additional, Shertel, Tara, additional, and Lange, Nicholas W., additional

Published
2022
Full Text
View/download PDF

11. Guiding therapeutic plasma exchange for antibody‐mediated rejection treatment in lung transplant recipients – a retrospective study

Author

Timofeeva, Olga A., primary, Choe, Jason, additional, Alsammak, Mohamed, additional, Yoon, Edward J., additional, Geier, Steven S., additional, Mathew, Leena, additional, McCollick, Amanda, additional, Carney, Kevin, additional, Au, Jenny, additional, Diamond, Adam, additional, Galli, Jonathan A., additional, Shenoy, Kartik, additional, Mamary, Albert, additional, Sehgal, Sameep, additional, Mulhall, Patrick, additional, Toyoda, Yoshiya, additional, Shigemura, Norihisa, additional, Cordova, Francis, additional, Criner, Gerald, additional, and Brown, James C., additional

Published
2021
Full Text
View/download PDF

13. SARS‐CoV‐2 infection increases tacrolimus concentrations in solid‐organ transplant recipients

Author

Salerno, David M., primary, Kovac, Danielle, additional, Corbo, Heather, additional, Jennings, Douglas L., additional, Lee, Jennifer, additional, Choe, Jason, additional, Scheffert, Jenna, additional, Hedvat, Jessica, additional, Chen, Justin, additional, Tsapepas, Demetra, additional, Rosenblatt, Russell, additional, Samstein, Benjamin, additional, Halazun, Karim, additional, Verna, Elizabeth, additional, Pereira, Marcus, additional, Brennan, Corey, additional, Husain, Syed A., additional, Mohan, Sumit, additional, and Brown, Robert S., additional

Published
2021
Full Text
View/download PDF

15. P139 Dilution studies establish hla donor-specific antibodies as a predictive biomarker for selection of amr treatment in lung transplant recipients

Author

Timofeeva, Olga A., primary, Carney, Kevin, additional, Choe, Jason, additional, Yoon, Edward, additional, Alsammak, Mohamed, additional, Geier, Steven S., additional, Brown, James, additional, Au, Jenny, additional, Cordova, Francis, additional, Shigemura, Norihisa, additional, Toyoda, Yoshiya, additional, Shenoy, Kartik, additional, Mamary, Albert, additional, and Criner, Gerald, additional

Published
2019
Full Text
View/download PDF

16. The Impact of Statin Intensity on the Early Progression of Cardiac Allograft Vasculopathy.

Author

Huang X, Yuzefpolskaya M, Colombo PC, Choe J, Shertel T, and Jennings DL

Subjects
Humans, Male, Female, Retrospective Studies, Middle Aged, Follow-Up Studies, Prognosis, Risk Factors, Graft Rejection etiology, Graft Rejection pathology, Graft Rejection prevention & control, Graft Rejection drug therapy, Postoperative Complications prevention & control, Adult, Carotid Intima-Media Thickness, Graft Survival drug effects, Ultrasonography, Interventional, Coronary Artery Disease etiology, Coronary Artery Disease pathology, Heart Transplantation adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Allografts, Disease Progression
Abstract

Background: Limited research has compared the relative risks and benefits different statins have after heart transplantation (HT)., Method: We hypothesize that higher statin intensity is associated with a smaller degree of allograft intimal thickening on intravascular ultrasound (IVUS) at 1-year post-HT. Allograft intima-media thickness (IMT) on the first annual IVUS was retrospectively compared in patients initiated on a low-intensity statin (pravastatin 20 mg daily) versus moderate-intensity statin (atorvastatin 20 mg daily) post-HT., Results: A total of 172 adult patients were included (2018-2022, n = 86 in each group). At 1 year, the maximal IMT was lower in the moderate-intensity statin group, but the difference did not reach statistical significance. The LDL levels at 1 year trended lower with moderate-intensity statin therapy, while the rates of adverse reactions were not statistically different. A multivariate analysis of the logistic regression model showed moderate statin intensity at 12 months was protective, while donor-specific antibodies developed within the first-year posttransplant were associated with IMT ≥ 0.5 mm on the first annual IVUS., Conclusion: This study found that using moderate-intensity statin to prevent the early progression was as safe and possibly more effective than low-intensity statin therapy for the prevention of early cardiac allograft vasculopathy., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results